75
Participants
Start Date
November 30, 2011
Primary Completion Date
November 30, 2014
Study Completion Date
June 14, 2016
Clofarabine/Busulfan x 4
"* Clofarabine IV dose level: 40 mg/m2/day x 5 days~* Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
Peripheral blood stem cell transplant
Peripheral blood stem cell transplant, after pre-conditioning drug treatment
University of Pennsylvania, Philadelphia
University of Alabama, Birmingham, Birmingham
Vanderbuilt University, Nashville
University of Michigan Cancer Center, Ann Arbor
Medical College of Wisconsin, Milwaukee
Washington University at St Louis, St Louis
University of Kansas Medical Center, Kansas City
City of Hope National Medical Center, Duarte
University of Washington, Seattle
Hackensack University Medical Center, Hackensack
Hospital for Sick Children, Toronto
Princess Margaret Hospital, Toronto
Genzyme, a Sanofi Company
INDUSTRY
Otsuka Pharmaceutical Development & Commercialization, Inc.
INDUSTRY
University of Michigan Rogel Cancer Center
OTHER